Company news

Spyre Therapeutics, Inc. news in 2022

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 1, 2022

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

November 29, 2022

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

November 14, 2022

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

November 2, 2022

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

October 18, 2022

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

October 3, 2022

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

August 28, 2022

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

August 23, 2022

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

August 17, 2022

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

August 3, 2022

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

June 1, 2022

Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates

May 4, 2022

Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

May 4, 2022

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

April 11, 2022

Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

April 10, 2022

Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022

April 5, 2022

Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting

March 28, 2022

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates

March 7, 2022

Aeglea BioTherapeutics Withdraws Public Offering

February 9, 2022

Aeglea BioTherapeutics Announces Proposed Public Offering

February 8, 2022

Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency

January 24, 2022

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022

January 4, 2022

Decks in 2022